Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study

Thanyawee Puthanakit,Eakachai Prompetchara,Sivaporn Gatechompol,Chutitorn Ketloy,Arunee Thitithanyanont,Anan Jongkaewwattana,Supranee Buranapraditkun,Sasiwimol Ubolyam,Stephen J. Kerr,Jiratchaya Sophonphan,Tanakorn Apornpong,Wonngarm Kittanamongkolchai,Sarawut Siwamogsatham,Somchai Sriplienchan,Kanitha Patarakul,Tuangtip Theerawit,Pathariya Promsena,Rapisa Nantanee,Siwaporn Manomaisantiphap,Sarun Chokyakorn,Lina Hong,Mijo Samija,David C. Montefiori,Hongmei Gao,Amanda Eaton,Wassana Wijagkanalan,Mohamad-Gabriel Alameh,Drew Weissman,Kiat Ruxrungtham,Monta Tawan,Aungsumalin Sutjarit,Thutsanun Meepuksom,Jitthiwa Athipunjapong,Thidarat Jupimai,Juthamanee Moonwong,Rachaneekorn Nadsasarn,Sasiprapha Khamthi,Pornpavee Nuncharoen,Yanisar Chanpoom,Phattharapa Khamkhen,Nirunya Narupan,Siriwan Thongthip,Konsiri Soisoongnern,Chomnid Shanyip,Thanakan Rachpradit,Kanipha Sriphraram,Wassana Somhanwong,Timporn Boondamnern,Nittaya Boonnak,Nitiya Chomchey,Somporn Tipsuk,Suwanna Puttamaswin,Siriyapat Yewande,Plengsri Lertarom,Anuntaya Uanithirat,Anongnart Anuchadbut,Sararut Chanthaburanun,Katawut Tarawat,Apicha Mahanontharit,Wanida Sinthon,Sasitorn Plakunmonthonw,Suwat Wongmueang,Theera Dalodom,Bunruan Sopa,Nuchthida Phongam,Anchisa Sri-Arunsak,Umaporn Chobkarching,Channuwat Bouko,Sukanya Junseeha,Boonsri Phuphalicho,Palida Pingthaisong,Apichaya Khlaiphuengsin,Patcharee Pararit,Patcharin Eamyoung,Thitiporn Somjit,Thatri Iampornsin,Dutmanee Thongchomphunut,Suwimon Manopwisedjaroen,Thanida Laopanupong,Supanuch Ekronarongchai,Chanya Srisaowakarn,Yuparat Jantraphakorn,Kanjana Srisutthisamphan,Ponsuk Visudhipan Grandin,ChulaVac001-Phase 2 study team

DOI: https://doi.org/10.1038/s41598-023-49653-6

IF: 4.6

2024-01-30

Scientific Reports

Abstract:ChulaCov19 mRNA vaccine demonstrated promising phase 1 results. Healthy adults aged 18–59 years were double-blind randomised 4:1 to receive two intramuscular doses of ChulaCov19 50 μg or placebo. Primary endpoints were safety and microneutralization antibody against-wild-type (Micro-VNT50) at day 50. One hundred fifty adults with median (IQR) age 37 (30–46) years were randomised. ChulaCov19 was well tolerated, and most adverse events were mild to moderate and temporary. Geometric mean titres (GMT) of neutralizing titre against wild-type for ChulaCov19 on day 50 were 1367 IU/mL. T-cell IFN-γ-ELISpot showed the highest responses at one week (Day29) after dose 2 then gradually declined. ChulaCov19 50 μg is well tolerated and elicited high neutralizing antibodies and strong T-cell responses in healthy adults.

multidisciplinary sciences